NASDAQ:TTOO - T2 Biosystems Stock Price, Forecast & News

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

T2 Biosystems Inc (NASDAQ:TTOO) issued its earnings results on Tuesday, July, 30th. The medical equipment provider reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The medical equipment provider had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.95 million. T2 Biosystems had a negative return on equity of 1,263.80% and a negative net margin of 851.71%. The firm's revenue was down 53.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.32) earnings per share. View T2 Biosystems' Earnings History.

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for T2 Biosystems.

T2 Biosystems issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$8.7-9.6 million, compared to the consensus revenue estimate of $$9.32 million.

7 equities research analysts have issued 1 year target prices for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' stock price to reach $5.63 in the next twelve months. This suggests a possible upside of 389.4% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for T2 Biosystems.

News articles about TTOO stock have been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. T2 Biosystems earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for T2 Biosystems.

T2 Biosystems saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,730,000 shares, an increase of 11.3% from the September 30th total of 4,250,000 shares. Based on an average trading volume of 1,303,400 shares, the days-to-cover ratio is presently 3.6 days. Approximately 13.3% of the shares of the stock are short sold. View T2 Biosystems' Current Options Chain.

Some companies that are related to T2 Biosystems include Restoration Robotics (HAIR), Soliton (SOLY), iCAD (ICAD), TELA Bio (TELA), Spectral Medical (EDTXF), Cytosorbents (CTSO), BRAINSWAY LTD/S (BWAY), Neuronetics (STIM), STRATA Skin Sciences (SSKN), Liquidia Technologies (LQDA), Motus GI (MOTS), Nephros (NEPH), Apollo Endosurgery (APEN), Pro-Dex (PDEX) and Sensus Healthcare (SRTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Progenics Pharmaceuticals (PGNX), Exelixis (EXEL), Verastem (VSTM), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP) and Heron Therapeutics (HRTX).

T2 Biosystems' stock is owned by a number of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.75%), Millennium Management LLC (0.49%), Granahan Investment Management Inc. MA (0.47%), Focused Wealth Management Inc (0.09%), Virtu Financial LLC (0.07%) and Cable Hill Partners LLC (0.07%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.

TTOO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Virtu Financial LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, John Mcdonough, Michael J Cima, Michael Terrence Gibbs and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.

TTOO stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Granahan Investment Management Inc. MA, Creative Planning, Commonwealth Equity Services LLC, Ironwood Financial llc, Founders Capital Management, Focused Wealth Management Inc and Cable Hill Partners LLC. View Insider Buying and Selling for T2 Biosystems.

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TTOO stock can currently be purchased for approximately $1.15.

T2 Biosystems has a market capitalization of $53.68 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.

The official website for T2 Biosystems is http://www.t2biosystems.com/.

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]